Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
- DOI
- 10.1016/j.clbc.2016.05.006
- Published
- 2016 Oct
- Container
- Clinical breast cancer
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.clbc.2016.05.006,
title = {Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.},
author = {Yardley DA and Ward PJ and Daniel BR and Eakle JF and Lamar RE and Lane CM and Hainsworth JD},
year = {2016},
journal = {Clinical breast cancer},
doi = {10.1016/j.clbc.2016.05.006},
url = {https://doi.org/10.1016/j.clbc.2016.05.006}
}RIS
TY - JOUR TI - Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial. AU - Yardley DA AU - Ward PJ AU - Daniel BR AU - Eakle JF AU - Lamar RE AU - Lane CM AU - Hainsworth JD PY - 2016 JO - Clinical breast cancer DO - 10.1016/j.clbc.2016.05.006 UR - https://doi.org/10.1016/j.clbc.2016.05.006 ER -
APA
DA, Y., PJ, W., BR, D., JF, E., RE, L., CM, L., & JD, H. (2016). Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.. Clinical breast cancer. https://doi.org/10.1016/j.clbc.2016.05.006
Source records
- pubmed · retrieved 2026-09-26T21:36:21.240Z